Teva Pharma (TEVA) Guides FY09, FY10 Inline With the Street
More News related to TEVA
- Abbott (ABT) sues Teva (TEVA) over its drug for kidney patients, Zemplar
- Merriman Curhan Ford Initiates Coverage on Antares Pharma (AIS) with a Buy; Cutting Edge Drug Delivery Business
- Teva Pharma (TEVA) Gets Final U.S. FDA Approval for Generic Prevacid
- Teva Receives Final Approval for Generic Prevacid(R) Delayed-Release Capsules
- Teva Pharma (TEVA) Announces Generic Version of Prevacid Does Not Infringe on Patents
More News related to Guidance
- Brush Engineered Materials (BW) Spikes Higher Amid Sidoti Upgrade
- Bernstein Upgrades Shire (SHPGY) to Outperform; Lifts Target to $65
- Deere (DE) Shares Outperforming as Morgan Stanley Upgrades to Overweight
- AnnTaylor (ANN) Shares Rallying as Analyst Sees Attractive Entry Point, Upgrades to Overweight
- Rodman & Renshaw Upgrades Origin Agritech (SEED) to Market Outperform
Teva Pharma (Nasdaq: TEVA) sees FY09 EPS of $3.30-$3.40, versus the consensus of $3.36, and FY10 EPS of $4.40-$4.60, versus the Street estimate of $4.48.
Related Categories
GuidanceStocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
